Transthyretin-Related Familial Amyloid Polyneuropathy: In the Light of New Developments/Yeni Gelismeler Isiginda Transtiretin Iliskili Ailevi Amiloid Polinoropatisi

Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) is caused by gain-of-toxic-function of TTR, which dissociates from its native tetramer form to a monomer form and aggregates in several tissues and organs. Mutations in the TTR gene lead to this amyloidogenic transformation and cause au...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Türk nöroloji dergisi 2017-09, Vol.23 (3), p.105
Hauptverfasser: Cakar, Arman, Tekce, Hacer Durmus, Deymeer, Feza, Serdaroglu, Piraye Oflazer, Parman, Yesim G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 3
container_start_page 105
container_title Türk nöroloji dergisi
container_volume 23
creator Cakar, Arman
Tekce, Hacer Durmus
Deymeer, Feza
Serdaroglu, Piraye Oflazer
Parman, Yesim G
description Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) is caused by gain-of-toxic-function of TTR, which dissociates from its native tetramer form to a monomer form and aggregates in several tissues and organs. Mutations in the TTR gene lead to this amyloidogenic transformation and cause autosomal dominant disease. TTR-FAP typically causes sensorimotor FAP accompanied by autonomic involvement, but considerable phenotypic diversity is noted between different mutation types. In the event of clinical suspicion, TTR gene sequencing and pathologic confirmation are the recommended paths to follow. Significant improvement has been achieved in treating the disease over the past 20 years, starting with liver transplantation, followed by tetramer stabilizers and TTR-lowering therapies. Although there are still some uncertainties in diagnosing and treating TTR-FAP, recent advances are promising, especially in the field of treatment. Keywords: Amyloidosis, transthyretin, polyneuropathy, genetics, neuropathy Oz Transiretin iliskili ailevi amiloid polinoropatisi (TTR-FAP), vucutta tetramer formda bulunan TTR'nin monomer hale gelerek toksik ozellik kazanmasi ve cesitli doku ve organlarda birikmesi sonucunda gelisir. TTR genindeki mutasyonlar, proteine amiloidojenik ozellik kazandirmakta ve otozomal dominant gecisli hastaliga neden olmaktadir. TTR-FAP tipik olarak otonom tutulumun eslik ettigi sensorimotor noropatiye neden olur, ancak farkli mutasyon tipleri arasinda ciddi fenotipik farklilik belirtilmistir. Klinik suphe halinde genetik ve patolojik inceleme yapilmasi gerekmektedir. Son 20 yilda, karaciger transplantasyonu ile baslayan, tetramer stabilizatorlerin ve TTR yapimini baskilayan ilaclarin klinik calismalarda ciddi etkisinin gosterilmesi ile devam eden surecte tedavi acisindan onemli yol alinmistir. Hastaligin tani ve tedavisinde hala bazi belirsizlikler olmakla birlikte, ozellikle tedavi alanindaki son gelismeler umit vericidir. Anahtar Kelimeler: Amiloidoz, transtiretin, polinoropati, genetik, noropati
doi_str_mv 10.4274/tnd.03206
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A532581428</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A532581428</galeid><sourcerecordid>A532581428</sourcerecordid><originalsourceid>FETCH-LOGICAL-g678-2aa8dc456420970ede961c604c2345599901c86a8fb3849d8a0aaa95914fc6763</originalsourceid><addsrcrecordid>eNptj7FOwzAQhj2ARFU68AaWmNM6iePYbFGhJVIFCHWAqTLxJT1wnCoOoL4PD4rVdmDgbviH--4-HSFXMZvyJOezwZkpSxMmzsgoTlkcMZG8XJCJ9-8sVKpyJdIR-Vn32vlhu-9hQBc9g9UDGLrQLVrUlhbt3nZo6FNn9w4--26nA3xDS0eHLdAVNtuBdjV9gG96C19gu10LbvCzV3BIl2DRt2Chp6XHBp3R9CjEg4-WYf4RTLRAC18hgvakQ9cdbOjxkpzX2nqYnHJM1ou79fw-Wj0uy3mxihqRyyjRWpqKZ4InTOUMDCgRV4LxKkl5limlWFxJoWX9lkqujNRMa60yFfO6ErlIx-T6eLbRFjbo6m7oddWirzZFliaZjHkiAzX9hwptoMWqc1CHV_4u_AJsK32A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Transthyretin-Related Familial Amyloid Polyneuropathy: In the Light of New Developments/Yeni Gelismeler Isiginda Transtiretin Iliskili Ailevi Amiloid Polinoropatisi</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Cakar, Arman ; Tekce, Hacer Durmus ; Deymeer, Feza ; Serdaroglu, Piraye Oflazer ; Parman, Yesim G</creator><creatorcontrib>Cakar, Arman ; Tekce, Hacer Durmus ; Deymeer, Feza ; Serdaroglu, Piraye Oflazer ; Parman, Yesim G</creatorcontrib><description>Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) is caused by gain-of-toxic-function of TTR, which dissociates from its native tetramer form to a monomer form and aggregates in several tissues and organs. Mutations in the TTR gene lead to this amyloidogenic transformation and cause autosomal dominant disease. TTR-FAP typically causes sensorimotor FAP accompanied by autonomic involvement, but considerable phenotypic diversity is noted between different mutation types. In the event of clinical suspicion, TTR gene sequencing and pathologic confirmation are the recommended paths to follow. Significant improvement has been achieved in treating the disease over the past 20 years, starting with liver transplantation, followed by tetramer stabilizers and TTR-lowering therapies. Although there are still some uncertainties in diagnosing and treating TTR-FAP, recent advances are promising, especially in the field of treatment. Keywords: Amyloidosis, transthyretin, polyneuropathy, genetics, neuropathy Oz Transiretin iliskili ailevi amiloid polinoropatisi (TTR-FAP), vucutta tetramer formda bulunan TTR'nin monomer hale gelerek toksik ozellik kazanmasi ve cesitli doku ve organlarda birikmesi sonucunda gelisir. TTR genindeki mutasyonlar, proteine amiloidojenik ozellik kazandirmakta ve otozomal dominant gecisli hastaliga neden olmaktadir. TTR-FAP tipik olarak otonom tutulumun eslik ettigi sensorimotor noropatiye neden olur, ancak farkli mutasyon tipleri arasinda ciddi fenotipik farklilik belirtilmistir. Klinik suphe halinde genetik ve patolojik inceleme yapilmasi gerekmektedir. Son 20 yilda, karaciger transplantasyonu ile baslayan, tetramer stabilizatorlerin ve TTR yapimini baskilayan ilaclarin klinik calismalarda ciddi etkisinin gosterilmesi ile devam eden surecte tedavi acisindan onemli yol alinmistir. Hastaligin tani ve tedavisinde hala bazi belirsizlikler olmakla birlikte, ozellikle tedavi alanindaki son gelismeler umit vericidir. Anahtar Kelimeler: Amiloidoz, transtiretin, polinoropati, genetik, noropati</description><identifier>ISSN: 1301-062X</identifier><identifier>DOI: 10.4274/tnd.03206</identifier><language>eng</language><publisher>Galenos Yayinevi Tic. Ltd</publisher><subject>Amyloidosis ; Development and progression ; Genetic aspects ; Liver transplantation ; Polyneuropathies</subject><ispartof>Türk nöroloji dergisi, 2017-09, Vol.23 (3), p.105</ispartof><rights>COPYRIGHT 2017 Galenos Yayinevi Tic. Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Cakar, Arman</creatorcontrib><creatorcontrib>Tekce, Hacer Durmus</creatorcontrib><creatorcontrib>Deymeer, Feza</creatorcontrib><creatorcontrib>Serdaroglu, Piraye Oflazer</creatorcontrib><creatorcontrib>Parman, Yesim G</creatorcontrib><title>Transthyretin-Related Familial Amyloid Polyneuropathy: In the Light of New Developments/Yeni Gelismeler Isiginda Transtiretin Iliskili Ailevi Amiloid Polinoropatisi</title><title>Türk nöroloji dergisi</title><description>Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) is caused by gain-of-toxic-function of TTR, which dissociates from its native tetramer form to a monomer form and aggregates in several tissues and organs. Mutations in the TTR gene lead to this amyloidogenic transformation and cause autosomal dominant disease. TTR-FAP typically causes sensorimotor FAP accompanied by autonomic involvement, but considerable phenotypic diversity is noted between different mutation types. In the event of clinical suspicion, TTR gene sequencing and pathologic confirmation are the recommended paths to follow. Significant improvement has been achieved in treating the disease over the past 20 years, starting with liver transplantation, followed by tetramer stabilizers and TTR-lowering therapies. Although there are still some uncertainties in diagnosing and treating TTR-FAP, recent advances are promising, especially in the field of treatment. Keywords: Amyloidosis, transthyretin, polyneuropathy, genetics, neuropathy Oz Transiretin iliskili ailevi amiloid polinoropatisi (TTR-FAP), vucutta tetramer formda bulunan TTR'nin monomer hale gelerek toksik ozellik kazanmasi ve cesitli doku ve organlarda birikmesi sonucunda gelisir. TTR genindeki mutasyonlar, proteine amiloidojenik ozellik kazandirmakta ve otozomal dominant gecisli hastaliga neden olmaktadir. TTR-FAP tipik olarak otonom tutulumun eslik ettigi sensorimotor noropatiye neden olur, ancak farkli mutasyon tipleri arasinda ciddi fenotipik farklilik belirtilmistir. Klinik suphe halinde genetik ve patolojik inceleme yapilmasi gerekmektedir. Son 20 yilda, karaciger transplantasyonu ile baslayan, tetramer stabilizatorlerin ve TTR yapimini baskilayan ilaclarin klinik calismalarda ciddi etkisinin gosterilmesi ile devam eden surecte tedavi acisindan onemli yol alinmistir. Hastaligin tani ve tedavisinde hala bazi belirsizlikler olmakla birlikte, ozellikle tedavi alanindaki son gelismeler umit vericidir. Anahtar Kelimeler: Amiloidoz, transtiretin, polinoropati, genetik, noropati</description><subject>Amyloidosis</subject><subject>Development and progression</subject><subject>Genetic aspects</subject><subject>Liver transplantation</subject><subject>Polyneuropathies</subject><issn>1301-062X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptj7FOwzAQhj2ARFU68AaWmNM6iePYbFGhJVIFCHWAqTLxJT1wnCoOoL4PD4rVdmDgbviH--4-HSFXMZvyJOezwZkpSxMmzsgoTlkcMZG8XJCJ9-8sVKpyJdIR-Vn32vlhu-9hQBc9g9UDGLrQLVrUlhbt3nZo6FNn9w4--26nA3xDS0eHLdAVNtuBdjV9gG96C19gu10LbvCzV3BIl2DRt2Chp6XHBp3R9CjEg4-WYf4RTLRAC18hgvakQ9cdbOjxkpzX2nqYnHJM1ou79fw-Wj0uy3mxihqRyyjRWpqKZ4InTOUMDCgRV4LxKkl5limlWFxJoWX9lkqujNRMa60yFfO6ErlIx-T6eLbRFjbo6m7oddWirzZFliaZjHkiAzX9hwptoMWqc1CHV_4u_AJsK32A</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Cakar, Arman</creator><creator>Tekce, Hacer Durmus</creator><creator>Deymeer, Feza</creator><creator>Serdaroglu, Piraye Oflazer</creator><creator>Parman, Yesim G</creator><general>Galenos Yayinevi Tic. Ltd</general><scope/></search><sort><creationdate>20170901</creationdate><title>Transthyretin-Related Familial Amyloid Polyneuropathy: In the Light of New Developments/Yeni Gelismeler Isiginda Transtiretin Iliskili Ailevi Amiloid Polinoropatisi</title><author>Cakar, Arman ; Tekce, Hacer Durmus ; Deymeer, Feza ; Serdaroglu, Piraye Oflazer ; Parman, Yesim G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g678-2aa8dc456420970ede961c604c2345599901c86a8fb3849d8a0aaa95914fc6763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Amyloidosis</topic><topic>Development and progression</topic><topic>Genetic aspects</topic><topic>Liver transplantation</topic><topic>Polyneuropathies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cakar, Arman</creatorcontrib><creatorcontrib>Tekce, Hacer Durmus</creatorcontrib><creatorcontrib>Deymeer, Feza</creatorcontrib><creatorcontrib>Serdaroglu, Piraye Oflazer</creatorcontrib><creatorcontrib>Parman, Yesim G</creatorcontrib><jtitle>Türk nöroloji dergisi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cakar, Arman</au><au>Tekce, Hacer Durmus</au><au>Deymeer, Feza</au><au>Serdaroglu, Piraye Oflazer</au><au>Parman, Yesim G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transthyretin-Related Familial Amyloid Polyneuropathy: In the Light of New Developments/Yeni Gelismeler Isiginda Transtiretin Iliskili Ailevi Amiloid Polinoropatisi</atitle><jtitle>Türk nöroloji dergisi</jtitle><date>2017-09-01</date><risdate>2017</risdate><volume>23</volume><issue>3</issue><spage>105</spage><pages>105-</pages><issn>1301-062X</issn><abstract>Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) is caused by gain-of-toxic-function of TTR, which dissociates from its native tetramer form to a monomer form and aggregates in several tissues and organs. Mutations in the TTR gene lead to this amyloidogenic transformation and cause autosomal dominant disease. TTR-FAP typically causes sensorimotor FAP accompanied by autonomic involvement, but considerable phenotypic diversity is noted between different mutation types. In the event of clinical suspicion, TTR gene sequencing and pathologic confirmation are the recommended paths to follow. Significant improvement has been achieved in treating the disease over the past 20 years, starting with liver transplantation, followed by tetramer stabilizers and TTR-lowering therapies. Although there are still some uncertainties in diagnosing and treating TTR-FAP, recent advances are promising, especially in the field of treatment. Keywords: Amyloidosis, transthyretin, polyneuropathy, genetics, neuropathy Oz Transiretin iliskili ailevi amiloid polinoropatisi (TTR-FAP), vucutta tetramer formda bulunan TTR'nin monomer hale gelerek toksik ozellik kazanmasi ve cesitli doku ve organlarda birikmesi sonucunda gelisir. TTR genindeki mutasyonlar, proteine amiloidojenik ozellik kazandirmakta ve otozomal dominant gecisli hastaliga neden olmaktadir. TTR-FAP tipik olarak otonom tutulumun eslik ettigi sensorimotor noropatiye neden olur, ancak farkli mutasyon tipleri arasinda ciddi fenotipik farklilik belirtilmistir. Klinik suphe halinde genetik ve patolojik inceleme yapilmasi gerekmektedir. Son 20 yilda, karaciger transplantasyonu ile baslayan, tetramer stabilizatorlerin ve TTR yapimini baskilayan ilaclarin klinik calismalarda ciddi etkisinin gosterilmesi ile devam eden surecte tedavi acisindan onemli yol alinmistir. Hastaligin tani ve tedavisinde hala bazi belirsizlikler olmakla birlikte, ozellikle tedavi alanindaki son gelismeler umit vericidir. Anahtar Kelimeler: Amiloidoz, transtiretin, polinoropati, genetik, noropati</abstract><pub>Galenos Yayinevi Tic. Ltd</pub><doi>10.4274/tnd.03206</doi></addata></record>
fulltext fulltext
identifier ISSN: 1301-062X
ispartof Türk nöroloji dergisi, 2017-09, Vol.23 (3), p.105
issn 1301-062X
language eng
recordid cdi_gale_infotracmisc_A532581428
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Amyloidosis
Development and progression
Genetic aspects
Liver transplantation
Polyneuropathies
title Transthyretin-Related Familial Amyloid Polyneuropathy: In the Light of New Developments/Yeni Gelismeler Isiginda Transtiretin Iliskili Ailevi Amiloid Polinoropatisi
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T06%3A21%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transthyretin-Related%20Familial%20Amyloid%20Polyneuropathy:%20In%20the%20Light%20of%20New%20Developments/Yeni%20Gelismeler%20Isiginda%20Transtiretin%20Iliskili%20Ailevi%20Amiloid%20Polinoropatisi&rft.jtitle=T%C3%BCrk%20n%C3%B6roloji%20dergisi&rft.au=Cakar,%20Arman&rft.date=2017-09-01&rft.volume=23&rft.issue=3&rft.spage=105&rft.pages=105-&rft.issn=1301-062X&rft_id=info:doi/10.4274/tnd.03206&rft_dat=%3Cgale%3EA532581428%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A532581428&rfr_iscdi=true